Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pLenti6/V5-p53_R273H Citations (14)

Originally described in: Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.
Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW Neoplasia. 2008 May . 10(5):450-61. PubMed

Articles Citing pLenti6/V5-p53_R273H

Articles
P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. Hashimoto A, Oikawa T, Hashimoto S, Sugino H, Yoshikawa A, Otsuka Y, Handa H, Onodera Y, Nam JM, Oneyama C, Okada M, Fukuda M, Sabe H. J Cell Biol. 2016 Apr 11;213(1):81-95. doi: 10.1083/jcb.201510002. Epub 2016 Apr 4. PubMed
ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance. Hashimoto A, Hashimoto S, Sugino H, Yoshikawa A, Onodera Y, Handa H, Oikawa T, Sabe H. Oncogenesis. 2016 Sep 12;5(9):e259. doi: 10.1038/oncsis.2016.60. PubMed
p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation. Artigas N, Gamez B, Cubillos-Rojas M, Sanchez-de Diego C, Valer JA, Pons G, Rosa JL, Ventura F. Cell Death Differ. 2017 Dec;24(12):2022-2031. doi: 10.1038/cdd.2017.113. Epub 2017 Aug 4. PubMed
An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Li G, Montgomery JE, Eckert MA, Chang JW, Tienda SM, Lengyel E, Moellering RE. Nat Commun. 2017 Nov 24;8(1):1775. doi: 10.1038/s41467-017-01854-0. PubMed
Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Liao P, Zeng SX, Zhou X, Chen T, Zhou F, Cao B, Jung JH, Del Sal G, Luo S, Lu H. Mol Cell. 2017 Dec 21;68(6):1134-1146.e6. doi: 10.1016/j.molcel.2017.11.006. Epub 2017 Dec 7. PubMed
Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers. Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA. Mol Cancer Res. 2019 Aug;17(8):1652-1664. doi: 10.1158/1541-7786.MCR-19-0144. Epub 2019 May 20. PubMed
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JW. Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3. PubMed
The EGFR-TMEM167A-p53 Axis Defines the Aggressiveness of Gliomas. Segura-Collar B, Gargini R, Tovar-Ambel E, Hernandez-SanMiguel E, Epifano C, Perez de Castro I, Hernandez-Lain A, Casas-Tinto S, Sanchez-Gomez P. Cancers (Basel). 2020 Jan 14;12(1). pii: cancers12010208. doi: 10.3390/cancers12010208. PubMed
Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK. Cell Rep. 2021 Feb 9;34(6):108726. doi: 10.1016/j.celrep.2021.108726. PubMed
Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Jung S, Kim DH, Choi YJ, Kim SY, Park H, Lee H, Choi CM, Sung YH, Lee JC, Rho JK. Sci Rep. 2021 Oct 4;11(1):19667. doi: 10.1038/s41598-021-99267-z. PubMed
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. McCann JJ, Vasilevskaya IA, McNair C, Gallagher P, Neupane NP, de Leeuw R, Shafi AA, Dylgjeri E, Mandigo AC, Schiewer MJ, Knudsen KE. Oncogene. 2022 Jan;41(3):444-458. doi: 10.1038/s41388-021-01903-5. Epub 2021 Nov 12. PubMed
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. Mejia-Hernandez JO, Raghu D, Caramia F, Clemons N, Fujihara K, Riseborough T, Teunisse A, Jochemsen AG, Abrahmsen L, Blandino G, Russo A, Gamell C, Fox SB, Mitchell C, Takano EA, Byrne D, Miranda PJ, Saleh R, Thorne H, Sandhu S, Williams SG, Keam SP, Haupt Y, Haupt S. Cancers (Basel). 2022 Aug 16;14(16):3947. doi: 10.3390/cancers14163947. PubMed
mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters. Liu Y, Azizian NG, Sullivan DK, Li Y. Nat Commun. 2022 Nov 17;13(1):7047. doi: 10.1038/s41467-022-34890-6. PubMed
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors. Cui B, Song L, Wang Q, Li K, He Q, Wu X, Gao F, Liu M, An C, Gao Q, Hu C, Hao X, Dong F, Zhou J, Liu D, Song Z, Yan X, Zhang J, Bai Y, Mao Q, Yang X, Liang Z. Signal Transduct Target Ther. 2023 Sep 25;8(1):366. doi: 10.1038/s41392-023-01603-4. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.